Oncol 1991；9：389-93.
2) Harries M, Gore M. Part II：Chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncology 2002；3：537-45.
3) Gronlund B, Hogdall C, Hansen HH, Engelholm SA. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol 2001；83：128-34.
4) Rose PG, Fusco N, Fluellen L, Rodrigues M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998；16：1494-7.
5) The ICON and AGO collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovaian cancer：the ICON4/AGO-OVAR-2.2 trial. Lancet 2003；361：2099-106.
6) Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma：application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 2002；20：1238-47.
7) Ghamande S, Lele S, Marchetti D, Baker T, Odunsi K. Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. Int J Gynecol Cancer 2003；13：142-7.
8) Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997；15：187-92.
9) 野田起一郎，池田正典，工藤隆一，西谷巌，矢嶋聰，田中憲一，他．Paclitaxel（BMS-181339）の卵巣癌患者に対する臨床第Ⅱ相試験（3時間点滴静注）．癌と化学療法 1996；23：317-25.
10) Alberola V, Rosell R, Gonzalez-Larriba JL, Molina F, Ayala F, Garcia-Conde J, et al. Single agent taxol, 3-hour infusion, in untreated advanced non-small cell lung cancer. AnnOncol 1995；6：49-52.
11) Havrilesky LJ, Alvarez AA, Sayer RA, Lancaster JM, Soper JT, Berchuck A, et al. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol Oncol 2003；88：51-7.
12) Verschraegen CF, Sittisomwong T, Kudelka AP, Guedes E, Steger M, Nelson-Taylor T, et al. Docetaxel for patients with paclitaxel-resistant mullarian carcinoma. J ClinOncol 2000；18：2733-9.
13) Rose PG, Blesing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma：A Gynecologic Oncology Group Study. Gynecol Oncol 2003；88：130-5.
14) Katsumata N, Tsunematsu R, Tanaka K, Terashima Y, Ogita S, Hoshiai H, et al. A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer：A Japanese cooperative study. Ann Oncol 2000；11：1531-6.
15) Matsumoto K, Katsumata N, Andoh M, Yamanaka Y, Kitagawa R, Shimizu C, et al. Efficacy of irinotecan in patients with platinum and taxane-resistant ovarian cancer. Proc ASCO 2003；22：464（1863）.
16) Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, et al. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 2003；21：291-7.
17) Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma. a Gynecologic Oncology Group Study. J Clin Oncol 1998；16：405-10.
18) Harries M, Gore M. Chemotherapy for recurrent ovarian cancer. Part II：Chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. The Lancet Oncology 2002；3：537-45.
19) Markman M. Second-line treatment of ovarian cancer with single-agent gemcitabine. Semin Oncol 2002；29：9-10.
20) Meyer T, Nelstrop AE, Mahmoudi M, Rustin GJ. Weekly cisplatin and oral etoposide as

treatment for relapsed epithelial ovarian cancer. Ann Oncol 2001；12：1705-9.
21) van der Burg ME, de Wit R, van Putten WL, Logmans A, Kruit WH, Stoter G, et al. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer 2002；86：19-25.
22) 葛谷和夫．卵巣がん委員会：新規研究プロトコール案についてー卵巣がん研究 JGOG3015（特定研究）プロトコールについてー 第19回婦人科がん化学療法共同研究会記録集（別冊）．2002；37-44.
23) Maenpaa JU, Ala-Fossi SL, Kivinen ST, Pohto MK, Kaar KK, Jekunen AP. Docetaxel and irinotecan in the second-line treatment of ovarian cancer：final results of a phase II study. Proc ASCO 2002；21：224a (894).
24) Donovan KA, Greene PG, Shuster JL, Partridge EE, Tucker DC. Treatment preferences in recurrent ovarian cancer. Gynecol Oncol 2002；86：200-11.

第3章 胚細胞腫瘍

1) Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997；47：5-27.
2) Williams SD. Current management of ovarian germ cell tumors. Oncology 1994；8：53-60.
3) Albrektsen G, Heuch I, Kvale G. Full-term pregnancies and incidence of ovarian cancer of stromal and germ cell origin：A Norwegian prospective study. Br J Cancer 1997；75：767-70.
4) O'Conner DM, Norris HJ. The influence of grade on the outcome of stage I ovarian immature (malignant) teratomas and the reproducibility of grading. Int J Gynecol Pathol 1994；13：283-9.
5) Norris HJ, Zirken HJ, Benson WL. Immature (malignant) teratoma of the ovary：a clinical and pathologic study of 58 cases. Cancer 1976；37：2359-72.
6) Kurman RJ, Norris HJ. Malignant germ cell tumors of the ovary. Hum Pathol 1977；8：551-64.
7) Talerman A. Management of germ cell tumors of the ovary；in Kurman RJ (ed)：Blaustein's Pathology of the Female Genital Tract. New York, NY, Springer-Verlag 1987；659-721.
8) Williams SD. Ovarian germ cell tumors：an update. Semin Oncol 1998；25：407-13.
9) Gershenson DM. Managements of early ovarian cancer：germ cell and sex cord-stromal tumors. Gynecol Oncol 1994；55：S62-S72.
10) Peccatori F, Bonazzi C, Chiari S, Landoni F, Colombo N, Mangioni, et al. Surgical management of malignant ovarian germ-cell tumors：10 Year's experience of 129 patients. Obstet Gynecol 1995；86：367-72.
11) 高松愛，上坊敏子，岩谷弘明，立岡和弘，脇田邦夫，秦宏樹，他．卵巣悪性胚細胞腫瘍の臨床病理的検討．日癌治誌 1996；31：334-41.
12) National Cancer Institute, PDQ (R). med News. Treatment statement for Health Professional. Ovarian germ cell tumors (PDQ), 2002. https://www.meb.uni-bonn.de/cancer.gov/CDR0000062935.html.
13) Williams SD, Blessing JA, DiSaia PJ, Major FJ, Ball HG 3rd, Liao SY. Second-look laparotomy in ovarian germ cell tumors：the Gynecologic Oncology Group experience. Gynecol Oncol 1994；52：287-91.
14) Gershenson DM. The obsolescence of second-look laparotomy in the management of malignant ovarian germ cell tumors. Gynecol Oncol 1994；52：283-5.
15) Smith JP, Rutledge F. Advances in chemotherapy for gynecologic cancer. Cancer 1975；36：669-74.
16) Slayton RE, Hreshchyshyn MM, Silverberg SC, Shingleton HM, Park RC, DiSalia PJ, et al. Treatment of malignant ovarian germ cell tumors：response to vincristine, dactinomycin, and cyclophosphamide (preliminary report). Cancer 1978；42：390-8.
17) Gershenson DM, Del Junco G, Herson J, Rutledge FN. Endodermal sinus tumor of the ovary：the M. D. Anderson experience. Obstet Gynecol 1983；61：194-202.

18) Slayton RE, Park RC, Silverberg SG, Shingleton H, Creasman WT, Blessing JA. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary : A Gynecologic Oncology Group Study (a final report). Cancer 1985 ; 56 : 243-8.
19) Gershenson DM, Copeland LJ, Kavanagh JJ, Cangir A, Del Junco G, Saul PB, et al. Treatment of malignant nondysgermnomatous germ cell tumors of the ovary with vincristine, dactinomycin, and cyclophosphamide. Cancer 1985 ; 56 : 2756-61.
20) Gershenson DM, del Junco G, Silva EG, Copeland LJ, Wharton JT, Rutledge FN. Immature teratoma of the ovary. Obstet Gynecol 1986 ; 68 : 624-9.
21) Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977 ; 87 : 293-8.
22) Taylor MH, Depetrillo AD, Turner R. Vinblastine, bleomycin, and cisplatin in malignant germ cell tumors of the ovary. Cancer 1985 ; 56 : 1341-9.
23) Williams SD, Blessing JA, Moore DH, Homesley HD, Adcock L. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors : A trial of Gynecologic Oncology Group. Ann Intern Med 1989 ; 111 : 22-7.
24) Kumar L, Bhargawa VL, Kumar S. Cisplatin, vinblastine and bleomycin in advanced and relapsed germ cell tumours of ovary. Asia Oceania J Obstet Gynecol 1993 ; 19 : 133-40.
25) Williams SD, Birch R, Einhorn L, Irwin L, Greco A, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. New Engl J Med 1987 ; 316 : 1435-40.
26) Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL, et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 1990 ; 8 : 715-20.
27) Williams SD, Blessing JA, Hatch KD, Homesley HD. Chemotherapy of advanced dysgerminoma : trials of the Gynecologic Oncology Group. J Clin Oncol 1991 ; 9 : 1950-5.
28) Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin : a trial of the Gynecologic Oncology Group. J Clin Oncol 1994 ; 12 : 701-6.
29) de Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW, et al, Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma : a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997 ; 15 : 1837-43.
30) Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors : a multiinstitutional study. J Clin Oncol 1993 ; 11 : 598-606.
31) Loehrer PJ Sr, Lauer R, Roth BJ, Williams SD, Kalasinski LA, Einhorn LH. Salvage therapy in recurrent germ cell cancer : ifosfamide and cisplatin plus either vinblastine or etoposide. [published erratum appears in Ann Intern Med 1988 ; 109 : 846]. Ann Intern Med 1988 ; 109 : 540-6.
32) McCaffrey JA, Mazumdar M, Bajorin DF, Bosl GJ, Vlamis V, Motzer RJ. Ifosfamide-and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors : response and survival. J Clin Oncol 1997 ; 15 : 2559-63.
33) Broun ER, Nichols CR, Kneebone P, Williams SD, Loehrer PJ, Einhorn LH, et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1992 ; 117 : 124-8.
34) Linkesch W, Greinix HT, Hocker P, Krainer M, Wagner A. Longterm follow up of phase Ⅰ/Ⅱ trial of ultra-high carboplatin, VP16, cyclophosphamide with ABMT in refractory or relapsed NSGCT. Proceeding of the 12th Am Soc Clin Oncol 1993 ; 232 (abstr 717).
35) Motzer RJ, Mazumdar M, Bosl GJ, Bajorin DF, Amsterdam A, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors : treatment results and prognostic factors for survival and toxicity. J Clnic Oncol 1996 ; 14 : 1098-105.

36) Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000 ; 18 : 2413-18.
37) Rick O, Bokemeyer C, Beyer J, Hartmann JT, Schwella N, Kingreen D, et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 2001 ; 19 : 81-8.
38) Nicosia SV, Matus-Ridley M, Meadows AT. Gonadal effects of cancer therapy in girls. Cancer 1985 ; 55 : 2364-72.
39) Gershenson DM. Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. J Clin Oncol 1988 ; 6 : 270-5.
40) Segelov E, Campbell J, Ng M, Tattersall M, Rome R, Free K, et al. Cisplatin-based chemotherapy for ovarian germ cell malignancies : The Australian experience. J Clin Oncol 1994 ; 12 : 378-84.
41) Mitchell PL, Al-Nasiri N, A'Hern R, Fisher C, Horwich A, Pinkerton CR, et al. Treatment of nondysgerminomatous ovarian germ cell tumors : An analysis of 69 cases. Cancer 1999 ; 85 : 2232-44.
42) Brewer M, Gershenson DM, Herzog CE, Mitchell MF, Silva EG, Wharton JT. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 1999 ; 17 : 2670-5.
43) Kanazawa K, Suzuki T, Sakumoto K. Treatment of malignant ovarian germ cell tumors with preservation of fertility : reproductive performance after persistent remission. Am J Clin Oncol 2000 ; 23 : 244-8.
44) Low JJ, Perrin LC, Crandon AJ, Hacker NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer 2000 ; 89 : 391-8.
45) Tangir J, Zelterman D, Ma W, Schwartz PE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol 2003 ; 101 : 251-57.
46) Nichols CR, Breeden ES, Loehrer PJ, Williams SD, Einhorn LH. Secondary leukemia associated with a conventional dose of etoposide : review of serial germ cell tumor protocols. J Natl cancer Inst 1993 ; 85 : 36-40.
47) Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rorth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ cell tumours. Lancet 1991 ; 338 : 359-63.
48) Jobo T, Hirano S, Hata H, Iwaya H, Sato R, Kuramoto H. Secondary acute leukemia following chemotherapy for ovarian cancer : report of five cases. Int J Clin Oncol 1999 ; 4 : 175-9.

和文索引

欧文索引

卵巣がん治療ガイドライン 2004年版

定価（本体1,800円＋税）

2004 年10月20日 第1版第1刷発行
2005 年 3 月 1 日 第2刷発行

編 集 日本婦人科腫瘍学会

発行者 川 井 弘 光

発行所 金原出版株式会社
〒113-8687 東京都文京区湯島2-31-14
電話 編集 ―― (03)3811-7162
営業 ―― (03)3811-7184
FAX ―― (03)3813-0288
振替口座 ―― 00120-4-151494
http://www.kanehara-shuppan.co.jp/

ISBN4-307-30085-8 印刷・製本／(株)真興社

JCLS <㈱日本著作出版権管理システム委託出版物>

小社は捺印または貼付紙をもって定価を変更致しません
乱丁，落丁のものはお買上げ書店または小社にてお取り替え致します

分担研究報告書（卵巣がん）資料３：構造化抄録用文献リスト

卵巣癌ガイドライン　－　構造化抄録リスト

1）　cGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stageⅢ and stage Ⅳ ovarian cancer.　N　Engl　J Med 1996 ; 334 : 1-6.

2) Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatinpaclitaxel versus cisplatincyclophosphamide in women with advanced epithelial ovarian cancer : threeyear results. J Natl Cancer Inst 2000 ; 92 : 699-708.

3) Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era : A metaanalysis. J Clin Oncol 2002 ; 20 : 1248-59.

4) Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. Impact of adjuvant chemotherapy and surgical staging in earlystage ovarian carcinoma : European Organisation for Research and Treatment of CancerAdjuvant Chemotherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst 2003 ; 95 : 113-25.

5) Vergote I , De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, et al. Prognostic importance of degree of differentiation and cyst rupture in stage・invasive epithelial ovarian carcinoma. Lancet 2001 ; 357 : 176-82.

6) Ahmed FY, Wiltshaw E, A'Hern RP, Nicol B, Shepherd J, Blake P, et al. Natural history and prognosis of untreated stage・epitherial ovarian carcinoma. J Clin Oncool 1996 ; 14 : 2968-75.

7) Baiocchi G, Raspagliesi F, Grosso G, Fontanelli R, Cobellis L, di Re E, et al. Early ovarian cancer : Is there a role for systematic pelvic and paraaortic lymphadenectomy? Int J Gynecol Cancer 1998 ; 8 : 103-8.

8) Kanazawa K, Suzuki T, Takashiki M. The validity and significance of substage・c by node involvement in epithelial ovarian cancer: Impact of nodal metastasis on patient survival. Gynecol Oncol 1999 ; 73 : 237-41.

9) van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995 ; 332 : 629-34.

10) Onda T, Yoshikawa H, Yasugi T, Mishima M, Nakagawa S, Yamada M, et al. Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to stage I / II patients and superior survival to other stage III patients. Cancer 1998 ; 83 : 1555-60.

11) Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, Moore DH, Small JM; Gynecologic Oncology Group.Secondary surgical cytoreduction for advanced ovarian carcinoma.N Engl J Med. 2004 Dec 9;351(24):2489-97.

12) De Poncheville L, Perrotin F, Lefrancg T, Lansac J, Body G. Does paraaortic lymphadenectomy have a benefit in the treatment of ovarian cancer that is apparently

confined to the ovaries? Eur J Cancer 2001 ; 37 : 210-5.

13) Obermair A, Sevelda P. Impact of second look laparotomy and secondary cytoreductive surgery at secondlook laparotomy in ovarian cancer patients. Acta Obstet Gynecl Scand 2001 ; 80 : 432-6.

14) Cass I, Li AJ, Runowicz CD, Fields AL, Goldberg GL, Leuchter RS, et al. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol 2001 ; 80 : 56-61.

15) Tay EH, Grant PT, Gebski ・, Hacker NF. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gyencol 2002 ; 99 : 1008-13.

16) Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2001 ; 83 : 504-12.

17) Munkarah A, Levenback C, Wolf JK, BodurkaBevers D, TortoleroLuna G, Morris RT, et al. Secondary cytoreductive surgery for localized intraabdominal recurrences in epithelial ovarian cancer. Gynecol Oncol 2001 ; 81 : 237-41.

18) Nicoletto MO, Tumolo S, Talamini R, Salvagno L, Franceschi S, Visona E, et al. Surgical second look in ovarian cancer: a randomized study in patients with laparoscopic complete remissionNortheastern Oncology Cooperative GroupOvarian Cancer Cooperative Group Study. J Clin Oncol 1997 ; 15 : 994-9.

19) NIH consensus conference. Ovarian cancer. Screening, treatment, and followup. NIH Consensus Development Panel on Ovarian Cancer. JAMA. 1995 ; 273 : 491-7.

20) Zanetta G, Rota S, Chiari S, Bonnazzi C Bratina G, Mangioni C. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma : a prospective study. J Clin Oncol 2001 ; 19 : 2658-64.

21) Jobo T, Yonaha H, Iwaya H, Kanai T, Kuramoto H. Conservative surgery for malignant ovarian tumor in women of childbearing age. Int J Clin Oncol 2000 ; 5 : 41-7.

22) Morice P, WicartPoque F, Rey A, ElHassan I, Pautier P, Lhomme C, et al. Results of conservative treatment in epithelial ovarian carcinoma. Cancer 2001 ; 92 : 2412-8.

23) Sakuragi N, Yamada H, Oikawa M, Okuyama K, Fujino T, Sagawa T, et al. Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0) . Gynecol Oncol 2000 ; 79 : 251-5.

24) Aabo K, Adams M, Adnitt P, Alberts DS, Athanazziou A, Barley V, et al. Chemotherapy in advanced ovarian cancer : four systematic metaanalyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998 ; 78 : 1479-87.

25) Ozols RF, Bundy BN, Greer BE, Fowley JM, ClarkePearson D, Burger RA, et al. Phase Ⅲ trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage ・ ovarian cancer : A Gynecologic Oncology Group Study. J Clin Oncol 2003 ; 21 : 3194-200.

26) du Bois A, Lueck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of

cisplatin/paclitaxel versus carboplatin/paclitaxel as firstline treatment of ovarian cancer. J Natl Cancer Inst 2003 ; 9 : 1320-9.

27) Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial : two parallel randomized phase III trials of adjuvant chemotherapy in patients with earlystage ovarian carcinoma. J Natl Cancer Inst 2003 ; 95 : 105-12.

28) Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, et al. International collaborative ovarian neoplasm trial 1 : a randomized trial of adjuvant chemotherapy in women with earlystage ovarian cancer. J Natl Cancer Inst 2003 ; 95 : 125-32.

29) Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener HC, et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992 ; 340 : 329-33.

30) Kaye SB, Paul J, Cassidy J, Lewis CR, Duncan ID, Gordon HK, et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish gynecology cancer trials group. J Clin Oncol 1996 ; 14 : 2113-9

31) Gore M, Mainwaring P, A' Hern R, MacFarlane V, Slevin M, Harper P, et al. Randomized trial of doseintensity with singleagent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol 1998 ; 16 : 2426-34.

32) Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB; Scottish Gynaecological Cancer Trials Group.Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91.

33) Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IVovarian cancer : a gynecologic oncology group study. J Clin Oncol 2000 ; 18 : 106-15.

34) ICON Group, Paclitaxel plus carboplatin versus standard chemotherapy with either singleagent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer : the ICON3 randomized trial. Lancet 2002 ; 360 : 505-15.

35) Bennett CL, Weeks JA, Somerfield MR, Feinglass J, Smith TJ. Use of hematopoietic colonystimulating factors : Comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. J Clin Oncol 1999 ; 17 : 3676-81.

36) Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. 2000 update of recommendations for the use of hematopoietic colonystimulating factors:evidencebased, clinical practice guidelines. J Clin Oncol 2000 ; 18 : 3558-85.

37) Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics : evidencebased, clinical practice guidelines. J Clin Oncol 1999 ; 17 : 2971-94.

38) Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hundelshausen B, et al.

Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIc ovarian carcinoma. Cancer 2001 ; 92 : 2585-91.

39) Young RC, Brady MF, Nieberg RM, Long HJ, Mayer AR, Lentz SS, et al. Adjuvant treatment for early ovarian cancer : a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatina gynecologic oncology group study. J Clin Oncol 2003 ; 2 : 4350-5.

40) Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD , et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxelbased chemotherapy : A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003 ; 21 : 2460-5.

41) Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996 ; 335 : 1950-5.

42) Markman M, Bundy BN, Alberts DS, Fowler JM, ClarkPearson DL, Carson LF, et al. Phase III trial of standarddose intravenous cisplatin plus paclitaxel versus moderately highdose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in smallvolume stage III ovarian carcinoma : an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001 ; 19 : 1001-7.

43) Trimble CL, Kosary C, Trimble EL. Longterm survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol 2002 ; 86 : 34-7.

44) Gronlund B, Hogdall C, Hansen HH, Engelholm SA. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol 2001 ; 83 : 128-34.

45) Rose PG, Fusco N, Fluellen L, Rodrigues M. Secondline therapy with paclitaxel and carboplatin for recurrent disease following firstline therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998 ; 16 : 1494-7.

46) The ICON and AGO collaborators. Paclitaxel plus platinumbased chemotherapy versus conventional platinumbased chemotherapy in women with relapsed ovaian cancer : the ICON4/AGOOVAR2.2 trial. Lancet 2003 ; 361 : 2099-106.

47) Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, et al. Retrospective analysis of carboplatin and paclitaxel as initial secondline therapy for recurrent epithelial ovarian carcinoma : application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 2002 ; 20 : 1238-47.

48) Donovan KA, Greene PG, Shuster JL, Partridge EE, Tucker DC. Treatment preferences in recurrent ovarian cancer. Gynecol Oncol 2002 ; 86 : 200-11.

49) Peccatori F, Bonazzi C, Chiari S, Landoni F, Colombo N, Mangioni, et al. Surgical

management of malignant ovarian germcell tumors : 10 Year' s experience of 129 patients. Obstet Gynecol 1995 ; 86 : 367-72.

50) Williams SD, Birch R, Einhorn L, Irwin L, Greco A, Loehrer PJ. Treatment of disseminated germcell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. New Engl J Med 1987 ; 316 : 1435-40.

51) Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin : a trial of the Gynecologic Oncology Group. J Clin Oncol 1994 ; 12 : 701-6.

52) de Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW, et al, Importance of bleomycin in combination chemotherapy for goodprognosis testicular nonseminoma : a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997 ; 15 : 1837-43.

53) McCaffrey JA, Mazumdar M, Bajorin DF, Bosl GJ, Vlamis V, Motzer RJ. Ifosfamideand cisplatincontaining chemotherapy as firstline salvage therapy in germ cell tumors : response and survival. J Clin Oncol 1997 ; 15 : 2559-63.

分担研究報告書（卵巣がん）資料４：Ovarian Cancer Treatment Guidelines
（2004年，日本婦人科腫瘍学会）から転載

Ovarian Cancer
Treatment Guidelines 2004

Japan Society of Gynecologic Oncology

Sponsorship:
Japan Society of Obstetrics and Gynecology
Japan Association of Obstetricians and Gynecologists
Japanese Gynecologic Oncology and Chemotherapy Study Group

Edited by: Japan Society of Gynecologic Oncology
Publisher: Minoru Ueki
Editorial Correspondence:
Japan Society of Gynecologic Oncology
Dai 2 Izumi-shoji Building,
4-2-6 Kojimachi, Chiyoda-ku,
Tokyo 102-0083, JAPAN
TEL: +81-3-3288-1033
FAX: +81-3-5275-1192
E-meil:gyne-oncol@jsgo.gr.jp
URL:http://www.jsgo.gr.jp
Printed by: Kanehara & Co., Ltd.

Ovarian Cancer Treatment Guidelines 2004

Translated and Edited by

Tadao TAKANO and Nobuo YAEGASHI, TOHOKU UNIVERSITY

Ovarian Cancer Treatment Guideline Investigative Committee

Committee Chairman	Yasuhiro Udagawa, M.D.
Committee Vice-Chairman	Nobuo Yaegashi, M.D.

Selection of Treatment Methods Based on Different Stages' Development Subcommittee

Committee Chairman	Mitsuaki Suzuki, M.D.
Committee Members	Daisuke Aoki, M.D., Aikou Okamoto, M.D., Satoru Sagae, M.D., Yoh Watanabe, M.D.

Types of Treatment and Their Indications Development Subcommittee

Committee Chairman	Kazuo Kuzuya, M.D.
Committee Members	Kiyoshi Ito, M.D., Shigemitsu Kobayashi, M.D., Hideki Sakamoto, M.D., Toshiko Joubou, M.D., Nobuyuki Susumu, M.D.

Treatments for Germ Cell Tumor Development Subcommittee

Committee Chairman	Toru Sugiyama, M.D.
Committee Members	Tsunekazu Kita M.D., Fumitaka Numa M.D., Kiyoshi Hasegawa, M.D., Keiichi Fujiwara M.D.

Evaluation Committee

Hiroshi Ishikura, M.D., Hisao Ito, M.D., Yoshiki Inoue, M.D., Naohiko Umesaki, M.D.,Tsunehisa Kaku, M.D., Noriyuki Katsumata, M.D., Koji Kanazawa, M.D., Toshiharu Kamura, M.D., Ichiro Kouno, M.D., Hiroyuki Kuramoto, M.D., Noriaki Sakuragi M.D., Masayuki Hatae, M.D., Masamichi Hiura, M.D., Hiroshi Hoshiai, M.D., Makoto Yasuda, M.D.

Preface to the English Language Edition

These Guidelines were developed to reduce the differences between institutions in the level of treatment provided to patients with ovarian cancer, by showing the therapies considered appropriate at the present time.

Japan Society of Gynecologic Oncology first set up a committee for the purpose of formulating these Guidelines. The approach taken by the committee was to evaluate relevant papers in this field, published in both Japan and overseas, collate those with high quality evidence based on sound scientific principles, organise the resultant body of information, and put together guidelines reflecting the therapies considered most appropriate.

Although much of the evidence underpinning these Guidelines has come from clinical trials in Europe and North America, in some areas priority was given to independently obtained Japanese evidence and consensuses. These Guidelines will therefore need to be subjected to a process of international evaluation. This is one of the reasons for the publication of this English language edition. I look forward to candid and unreserved comments from our overseas colleagues.

Kiichiro Noda
Honorary Chairperson
Japan Society of Gynecologic Oncology

Introduction to Japanese Edition

The first attempt in Japan to produce guidelines for the treatment of gynecological cancers occurred in 1997 when Japan Society of Obstetrics and Gynecology set up the "Exploratory Sub-committee for the Standardization of Treatment of Ovarian Cancer", chaired by Dr Hiroyuki Kuramoto. This group examined the evidence available at that time from Japan and overseas for the standard treatments for ovarian cancer, and their report was published 3 years later in the Society Journal. These findings were not accorded the status of official guidelines, however, as many were of the opinion that the time was not yet right, and they were not up to the standard expected of guidelines nowadays.

As we entered the new century, the release of the "Stomach Cancer Treatment Guidelines" gave new impetus for the production of cancer treatment guidelines. Japan Society of Gynecologic Oncology (under the ex-President Shiro Nozawa) decided to develop therapeutic guidelines for gynecological cancers, and set up a Guidelines Committee in 2002. The Committee decided to first produce guidelines for the treatment of ovarian cancer, for the reasons that both the incidence and death rate from ovarian cancer are increasing in recent years, and the prognosis is the poorest among gynecological cancers, with about half of all cases in advanced stages at the time of diagnosis.

The purpose of these "Ovarian Cancer Treatment Guidelines" is to provide doctors dealing with ovarian cancer in their everyday clinical practice with information concerning those treatments that have gained broad consensus as the most appropriate at the present time. Accordingly, their role is to provide advice to be considered in providing treatment to patients, not to affect the discretion of clinicians, or place restrictions on the therapeutic options available. The use of these guidelines in medical disputes or lawsuits would also be considered to contravene their purpose. Although Japan Society of Gynecologic Oncology is responsible for the content of these Guidelines, responsibility for the results of treatment belongs to the treating clinician.

In producing these guidelines, a Production Committee and an Evaluation Committee were set up within the Guidelines Committee. The Production Committee decided to make use of the abovementioned Japan Society of Obstetrics and Gynecology Sub-committee report. In their guidelines, they included primary epithelial ovarian cancers, ovarian tumors of low malignant potential, malignant or borderline malignant ovarian germ cell tumors, and their respective recurrences. A treatment algorithm is first given for each tumor type, then the main text for each heading, with explanatory comments and footnotes as necessary. The standards set by the Appropriate Use of Anticancer Drugs Guidelines Committee of Japan Society of Clinical Oncology were followed in assessing the quality of evidence, and the strength of recommendations. The draft guidelines went to the Evaluation Committee, then Society examiners, and were then presented to all the Society members. During this process, a number of suggestions and comments were incorporated into the document. The revised draft guidelines were then submitted to Japan Society of Obstetrics and Gynecology and Japan Association of Obstetricians and

Gynecologists, and after incorporating a number of suggestions from both societies, their approval was also obtained. Final approval was given at the General Meeting of Japan Society of Gynecologic Oncology held in the summer of 2004, leading to the publishing of this document.

It is of course our fervent wish that these Guidelines will be put to good use in the clinical situation. In addition, as we plan to produce revisions on a regular basis, we would be happy to receive criticisms and suggestions from as many clinicians as possible.

Finally, I would like to thank the following people for their hard work in producing these Guidelines: Professor Nobuo Yaegashi and the other Production Committee members, for their tireless and devoted work; the staff at the Editorial Department of Kanehara & Co., Ltd, for their tremendous efforts in editing these Guidelines, and everyone in the Society Office, who undertook the enormous task of collecting and organizing the mountain of paper produced in the process of putting together this document.

August 2004

Professor Yasuhiro Udagawa
Chairman
Ovarian Cancer Therapeutic Guidelines Committee
Japan Society of Gynecologic Oncology

Contents